Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $172.24M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 1.44M
Average 0.50M
Returns on capital
Pyxis Oncology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.1%
avg -28.2%
ROIC
-117.1%
avg -75.2%
ROA
-87.0%
avg -57.6%
Analysis
ROA is currently the strongest return metric at -87.0% versus its period average of -57.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer | USD 559.05K | 46 | 262.63K | 0.41% |
Thomas Civik | CEO & Chairman | USD 47.5K | 57 | 2.50M | 3.95% |
Stan Szpindor | Head of R&D Quality | — | — | — | — |
Shui He | Head of Biometrics | — | — | — | — |
Donna Regalado | Head of Human Resources | — | — | — | — |
Balu N. Balasubramanian | Interim Chief Technology Officer | — | — | — | — |
Charles T. Gombar | Senior Vice President of Portfolio & Program Management | — | — | — | — |
Hongwei Wang | Head of ADC Development & Clinical Strategy | — | — | — | — |
Marsha Crochiere | Head of Translational Medicine & Research | — | — | — | — |
Michael Bui | Senior Vice President of Global Regulatory Affairs | — | — | — | — |
Supriya Roth | Head of Commercial Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$51.52M
Sells
1
$107,100.00
Net Transaction Value
+$51.41M
Net buying
Most Active
GordonMD Global Investments LP
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | GordonMD Global Investments LP Indirect | Buy | $25.1M$25,102,000.00 |
| Oct 1, 26Oct 1, 2026 | GordonMD Global Investments LP Indirect | Buy | $0$0.00 |
| Oct 1, 26Oct 1, 2026 | GordonMD Global Investments LP Indirect | Buy | $26.4M$26,413,681.00 |
| Jun 30, 26Jun 30, 2026 | Dupont Jakob Direct | Sell | $107.1K$107,100.00 |
Summary
Insiders reported 3 buys worth $51.52M and 1 sells worth $107,100.00 over the last 12 months. That adds up to net buying of $51.41M. GordonMD Global Investments LP was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +54.6% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +54.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Pyxis Oncology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PYXS's management, answered from reported figures.
Who manages PYXS?
Pyxis Oncology, Inc. (PYXS) lists 11 active executives. The top listed executive is Stan Szpindor, Head of R&D Quality.
Are PYXS insiders buying or selling?
Recent insider activity shows net buying of $111.29M.
Continue the stock analysis
Jump to another research area for this company.